# A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

> **NCT02891603** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 40 (actual)

## Conditions studied

- Graft Vs Host Disease
- GVHD

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus
- **PROCEDURE:** Allogenic hematopoietic cell transplant (alloHCT)

## Key facts

- **NCT ID:** NCT02891603
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-08
- **Primary completion:** 2022-01-28
- **Final completion:** 2022-04-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891603, "A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02891603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*